Segment Information

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Segment Information

14.Segment Information

The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The Company manages its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker uses the revenues and earnings (losses) of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.

The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.

The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were $128,840 and $143,889 as of September 30, 2024 and December 31, 2023, respectively.

Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:

	Three Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,292	$	8,004	$	-			$	9,296
Cost of revenues (excluding amortization of acquired intangible assets)		-			238		3,645		-				3,883
Direct expenses		3,496			353		4,187		8,529				16,565
Segment contribution	$	(3,496	)	$	701	$	172	$	(8,529	)		$	(11,152	)
Indirect expenses									375		(a)		375
Loss from operations												$	(11,527	)
(a) Components of other
Amortization									375
Total other								$	375

	Three Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	1,427	$	2,359		$	-			$	3,786
Cost of revenues (excluding amortization of acquired intangible assets)		-			398		3,204			-				3,602
Direct expenses		4,887			350		1,901			9,074				16,212
Segment contribution	$	(4,887	)	$	679	$	(2,746	)	$	(9,074	)		$	(16,028	)
Indirect expenses										83,228		(b)		83,228
Loss from operations													$	(99,256	)
(b) Components of other
Change in fair value of contingent stock consideration										(39	)
Goodwill impairment										82,714
Amortization										553
Total other									$	83,228

Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:

	Nine Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	3,857	$	32,231	$	-			$	36,088
Cost of revenues (excluding amortization of acquired intangible assets)		-			952		6,694		-				7,646
Direct expenses		12,383			1,216		14,385		28,159				56,143
Segment contribution	$	(12,383	)	$	1,689	$	11,152	$	(28,159	)		$	(27,701	)
Indirect expenses									1,377		(a)		1,377
Loss from operations												$	(29,078	)
(a) Components of other
Amortization									1,377
Total other								$	1,377

	Nine Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	4,062	$	6,597		$	-			$	10,659
Cost of revenues (excluding amortization of acquired intangible assets)		-			1,355		5,052			-				6,407
Direct expenses		53,505			780		6,799			31,481				92,565
Segment contribution	$	(53,505	)	$	1,927	$	(5,254	)	$	(31,481	)		$	(88,313	)
Indirect expenses										117,289		(b)		117,289
Loss from operations													$	(205,602	)
(b) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Change in fair value of contingent stock consideration										(159	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										1,640
Total other									$	117,289